Epizyme Inc. (NASDAQ:EPZM) shares shot up 5% during mid-day trading on Monday . The stock traded as high as $8.92 and last traded at $8.75, with a volume of 316,076 shares traded. The stock had previously closed at $8.33.

Several research firms have issued reports on EPZM. Leerink Swann restated a “buy” rating on shares of Epizyme in a report on Tuesday, April 19th. HC Wainwright restated a “buy” rating on shares of Epizyme in a report on Monday, June 20th. Cowen and Company reiterated a “buy” rating on shares of Epizyme in a research note on Monday, June 20th. Mizuho reiterated a “buy” rating and issued a $18.00 price objective on shares of Epizyme in a research note on Monday, June 20th. Finally, Royal Bank Of Canada reiterated an “outperform” rating and issued a $26.00 price objective on shares of Epizyme in a research note on Monday, June 20th. One investment analyst has rated the stock with a hold rating and nine have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $23.11.

The stock’s 50 day moving average is $9.88 and its 200-day moving average is $10.44. The firm’s market capitalization is $505.38 million.

Epizyme (NASDAQ:EPZM) last issued its earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.49) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.52) by $0.03. On average, analysts forecast that Epizyme Inc. will post ($2.19) earnings per share for the current year.

In other Epizyme news, insider Robert A. Copeland sold 4,000 shares of the company’s stock in a transaction that occurred on Tuesday, July 5th. The stock was sold at an average price of $10.03, for a total value of $40,120.00. Following the completion of the sale, the insider now owns 4,000 shares of the company’s stock, valued at $40,120. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

An institutional investor recently bought a new position in Epizyme stock. California Public Employees Retirement System acquired a new position in Epizyme Inc. (NASDAQ:EPZM) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 170,000 shares of the biopharmaceutical company’s stock, valued at approximately $2,723,000. California Public Employees Retirement System owned 0.41% of Epizyme at the end of the most recent quarter.

Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company’s segment is the discovery and development of novel epigenetic therapies for cancer patients. It develops small molecule inhibitors of a class of enzymes known as histone methyltransferases, or HMTs.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.